Observational report examines COVID-19 antiviral prescription receipt in older US outpatientsStudy examines COVID-19 antiviral prescriptions for older adults in the U.S

An observational report described patterns of COVID-19 antiviral prescription receipt among outpatients aged 65 years and older in the United States. The report focused on this specific population but did not provide sample size, follow-up duration, or comparator group information. No specific results regarding prescription rates, effect sizes, absolute numbers, or statistical measures were reported in the available data.

Safety and tolerability information for antiviral prescriptions in this population was not reported in the summary. The report did not include details on adverse events, serious adverse events, or discontinuation rates associated with antiviral use among older outpatients.

Key limitations include the absence of reported results, lack of comparative data, and unspecified sample size and follow-up duration. The observational nature of the report means it can only describe patterns rather than establish causal relationships. Practice relevance is limited due to the absence of specific findings about prescription rates or comparative effectiveness in this vulnerable population.